I am the Chief of Stanford BMT and Cell Therapy Program that provides 750 cancer cell therapies annually. Our BMT-CT research fosters the development of both laboratory immunologists, and clinical translational researchers. Our allogeneic hematopoietic cell transplantation (alloHCT) research is optimizing graft content of HSC, conventional T lymphocyte, and regulatory T cell content in order to cures blood cancers via beneficial graft-v-tumor (GVT) immunity while reducing GVHD risk. Our CAR-T research provides the most direct targeting of cancer and is dramatically improving leukemia and Lymphoma with no GVHD risk. Our goal is to combine graft engineered allogeneic HCT with CAR-T benefit.
The Miklos lab pioneered protein microarray technologies to discover clinically relevant allogeneic antibodies. Our clinical trials established cGVHD therapeutic benefits using anti-B cell drugs rituximab and ibrutinib. More recently, our team developed human correlative assays to optimize CAR-T therapy including ctDNA MRD, flow cytometry tumor antigen quantification, Immune phenotype CAR-T characterization (CAR-FACS), and single cell RNA characterization of CAR-T cells.
Immunotherapy is revolutionizing cancer treatment and Stanford Cancer Cell Therapy Program is developing and evaluating the most promising chimeric antigen T-cell (CAR-T) therapies targeting CD19, CD20, CD22, CD79A, and BCMA.